$128.56
+1.1%Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Chairman, President & Chief Executive Officer
Compensation
$3,048,875
Corporate Vice President & Chief Compliance Officer
Corporate Vice President & Chief Human Resources Officer
Compensation
$564,684
Corporate Vice President & Chief Medical Officer
Corporate Vice President & President of Global Commercial
Compensation
$1,206,854
Corporate Vice President, General Counsel & Secretary
Compensation
$841,936
Executive Vice President & Chief Financial Officer
President & GM of Surgical
President, EMEA & Global Urology
Vice President & Chief Information Officer
Vice President of Investor Relations & Strategy Development
During the last 12 months, insiders have purchased $599K worth of TFX shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
5.2K
599.17K
0
0.00
+599K
+$599K
Kelly Liam
Director, Officer: Chairman, President & Ceo
$173K
Ryu Jaewon
Director
$173K
Randle Stuart A
Director
$116K
Krakauer Andrew A
Director
$115K
Haggerty Gretchen R
Director
$23K
No selling activity
Strong bullish signal with $599K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
TFX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | April 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 28, 2025 | May 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 01, 2024 | May 03, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 31, 2023 | March 31, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 30, 2022 | April 29, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 26, 2021 | April 30, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 27, 2020 | May 01, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 29, 2019 | May 03, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 30, 2018 | May 04, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 31, 2017 | May 05, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.